Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 2Neoplasm Metastasis 2Kidney Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma, Mucinous 1

Interventions

Specimen Handling 3Nivolumab 3Ipilimumab 3cabozantinib 2Magnetic Resonance Spectroscopy 2CTLA-4 Antigen 2Pluvicto 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Axitinib × 30 days × Clear all
NCT07227415 2026-06-04

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Pfizer

Phase 1/2 Recruiting
224 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡